Myrtelle is a gene therapy company that offers clinical trials for the treatment of rare monogenetic disorders.
Myrtelle has raised $30.5M in total funding. The most recent round was Series B. The last funding was announced in December 2025.
Myrtelle's investors include Panacea Venture.
Myrtelle is headquartered in Wakefield, United States.
Myrtelle is a gene therapy company that offers clinical trials for the treatment of rare monogenetic disorders.
Myrtelle is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Myrtelle — Funding & Investors." VCBacked, December 23, 2025, https://www.vcbacked.co/company/myrtelle. Accessed September 30, 2026.
VCBacked. (2025). Myrtelle — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/myrtelle
{{cite web |title=Myrtelle — Funding & Investors |url=https://www.vcbacked.co/company/myrtelle |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated